Drug Profile
Research programme: alpha-synuclein aggregation inhibitor - BiolineRx/Tel Aviv University
Alternative Names: EDP-32Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Tel Aviv University
- Developer BioLineRx; Tel Aviv University
- Class Peptides
- Mechanism of Action Alpha-synuclein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Parkinson's disease
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Parkinson's-disease in Israel
- 27 Sep 2013 Early research is ongoing in Israel
- 18 Dec 2012 Early research in Parkinson's disease in Israel (unspecified route)